Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 8:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 629 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: quinolone Clear all

Conditions: Dyslipidemia
Interventions: K-877 Low Dose, Moxifloxacin, Placebo, K-877 High Dose; Drug · Other
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Schizophrenia
Interventions: Elpipodect, Moxifloxacin, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Glendale, California • Orange, California • Hallandale, Florida + 1 more

Conditions: Gonorrhea Male
Interventions: Cefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090, Meningococcal Group B Vaccine, Influenza Vaccine, Tetanus-diptheria Vaccine; Drug · Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Crohn's Disease
Interventions: Fluconazole, Vancomycin, Neomycin, Ciprofloxacin, Polyethylene Glycol 3350, Promethazine, Fluconazole placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Uncomplicated Bacterial Cystitis
Interventions: Nitrofurantoin monohydrate/macrocrystals 100 mg BID x 3 days, ciprofloxacin 250 mg BID x 3 days; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Colorectal Cancer, CRC
Interventions: Standard of Care Chemotherapy + Metronidazole, ciprofloxacin, aspirin; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 2
States / cities: Richmond, Virginia

Conditions: Maternal Obesity
Interventions: Pyrroloquinoline quinone (PQQ), Placebo with soybean oil; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 40 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Bipolar Disorder, Alcoholism, Alcohol Abuse
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Schizophrenia
Interventions: Aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 709 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 52
States / cities: Bellevue, California • Garden Grove, California • Glendale, California + 43 more

Conditions: Patient Preference
Interventions: Dexamethasone, Standard of care surgery; Drug · Other
Lead sponsor: Ophthalmic Consultants of Long Island; Other
Eligibility: 22 Years to 100 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Garden City, New York

Conditions: Cardiovascular Diseases
Interventions: energy drink, Moxifloxacin 400mg, Placebo; Other
Lead sponsor: David Grant U.S. Air Force Medical Center; Federal
Eligibility: 18 Years to 40 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Travis Air Force Base, California

Conditions: Bladder Cancer
Interventions: cephalexin, surgical procedure, Ciprofloxacin; Drug · Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2007
U.S. locations: 90
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more

Conditions: Escherichia Coli Infections
Interventions: Levofloxacin, Placebo, Enteroaggregative E. coli (EAEC); Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Subjects, Cardiac Repolarization
Interventions: Placebo, ASP1941, Moxifloxacin; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Pancreatic Cancer
Interventions: Pembrolizumab, Ciprofloxacin 500mg PO BID days 1-29, Metronidazole 500mg PO TID days 1-29; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Months to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Gastro-Oesophageal Cancer
Interventions: Regorafenib, Nivolumab, Docetaxel, Paclitaxel, Irinotecan, Trifluridine/Tipracil; Drug · Biological
Lead sponsor: Australasian Gastro-Intestinal Trials Group; Network
Eligibility: 18 Years and older
Enrollment: 462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: Scottsdale, Arizona • Los Angeles, California • Sioux City, Iowa + 3 more

Conditions: Drug Toxicity
Interventions: HPN-100, HPN-100 or Placebo, Placebo, Moxifloxacin; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Alcoholism
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 14
States / cities: Farmington, Connecticut • New Haven, Connecticut • Indianapolis, Indiana + 11 more

Conditions: Autistic Disorder, Behavioral Symptoms
Interventions: Aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 55
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 49 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Aripiprazole; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 8 Years to 12 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Bipolar Disorder, Medication Adherence, Medication Non Adherence
Interventions: Abilify Maintena, Customized Adherence Enhancement (CAE); Drug · Behavioral
Lead sponsor: Martha Sajatovic; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cocaine-Related Disorders
Interventions: Aripiprazole, Placebos; Drug
Lead sponsor: Craig Rush; Other
Eligibility: 18 Years to 50 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Schizophrenia
Interventions: aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 16
States / cities: Anaheim, California • Cerritos, California • Chula Vista, California + 13 more

Conditions: Rheumatoid Arthritis
Interventions: SAR441566, Placebo, Ciprofloxacin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Search by objective public record fields.

A Thorough Corrected QT Interval Trial

A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)

Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae

Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease

A Pilot Comparison of Short-course Nitrofurantoin in Females With Uncomplicated Bacterial Cystitis in the Emergency Department

Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer

Evaluating Pyrroloquinoline Quinone (PQQ) for Improving Obese Pregnancy Outcomes

Aripiprazole for Bipolar Disorder and Alcohol Use Disorder

An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia

A Trial Evaluating Patient Preference of Dropless vs Drops Post Cataract Surgery

Evaluation of Energy Drinks on Electrocardiographic, Vascular and Hematologic Parameters in Healthy Volunteers

S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer

Enteroaggregative E.Coli (EAEC)

A Study of the Effect of ASP1941 on Cardiac Repolarization in Healthy Subjects

Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma

RegoNivo vs Standard of Care Chemotherapy in AGOC

Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100

Study of Aripiprazole in Subjects With Alcoholism

Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)

Study of Aripiprazole (Abilify) in Children With ADHD (Attention Deficit Hyperactivity Disorder)

CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)

Aripiprazole to Reduce Cocaine Relapse

Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders

A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566